Article

Tyrosine kinase inhibitor independent gene expression signature in CML offers new targets for LSPC eradication therapy

2022-07-02

Abstract excerpt

2 Tyrosine kinase inhibitors (TKI) have revolutionised the treatment of CML. However, TKI do not eliminate the leukaemia stem cells (LSC), which can reinitiate the disease. Thus, finding new therapeutic targets in CML LSC is key to finding a curative treatment. Using microarray datasets, we defined a list of 227 genes which were differentially expressed in CML LSC compared to healthy controls but were not affected...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 5ae20bbf-dab3-5292-885a-9c2be1e9945b
DOI: 10.1101/2022.06.30.498287

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 8 closest

Tyrosine kinase inhibitor independent gene expression signature in CML offers new targets for LSPC eradication therapyDOI 10.1101/2022.06.30.498287Read

Differentially expressed genes responsible for insensitivity of CD34+ cells to kinase inhibitors in patients with chronic myeloid leukemiaSemantic proximity Read

Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance.Semantic proximity Read

Characterization of Imatinib Resistant CML Leukemic Stem/Initiating Cells and Their Sensitivity to CBP/Catenin Antagonists.Semantic proximity Read

The impact of gene profiling in chronic myeloid leukaemia.Semantic proximity Read

Gene expression signature of primary imatinib-resistant chronic myeloid leukemia patientsSemantic proximity Read

Adaptive phenotypic modulations lead to therapy resistance in chronic myeloid leukemia cells.Semantic proximity Read

Identification of genes involved in imatinib resistance in CML: a gene-expression profiling approach.Semantic proximity Read

Gene expression profiling of imatinib and PD166326-resistant CML cell lines identifies Fyn as a gene associated with resistance to BCR-ABL inhibitorsSemantic proximity Read